Oral estrogen, but not patch, boosts clot risk with HRT

Article

Oral, but not transdermal, estrogen is associated with a fourfold increase in the risk of venous thromboembolism (VTE) in postmenopausal women taking hormone therapy, and VTE risk is also influenced by the progestogen derivative used, according to the results of a study published in the Feb. 20 issue of Circulation.

Oral, but not transdermal, estrogen is associated with a fourfold increase in the risk of venous thromboembolism (VTE) in postmenopausal women taking hormone therapy, and VTE risk is also influenced by the progestogen derivative used, according to the results of a study published in the Feb. 20 issue of Circulation.

Pierre-Yves Scarabin, MD, of Inserm Unit 780 in Villejuif, France, and colleagues examined 271 postmenopausal women with idiopathic VTE and 610 matched controls.

Compared with non-users of estrogen, the risk of VTE was higher for users of oral rather than transdermal estrogen (OR, 4.2 and 0.9, respectively). Micronized progesterone and pregnane derivatives were not associated with VTE (OR, 0.7 and 0.9, respectively), while norpregnane derivatives increased the risk of VTE (OR, 3.9).

Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115:840-845.

Related Videos
One year out: Fezolinetant displays patient satisfaction for managing hot flashes | Image Credit: sutterhealth.org
Addressing maternal health inequities: Insights from CDC's Wanda Barfield | Image Credit: cdc.gov
Addressing racial and ethnic disparities in brachial plexus birth Injury | Image Credit: shrinerschildrens.org
Innovations in prenatal care: Insights from ACOG 2024 | Image Credit:  uofmhealth.org.
Unlocking therapeutic strategies for menopausal cognitive decline | Image Credit: uclahealth.org.
Navigating menopause care: Expert insights from ACOG 2024 | Image Credit: mayo.edu.
raanan meyer, md
Related Content
© 2024 MJH Life Sciences

All rights reserved.